Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
237.55B
Market cap237.55B
Price-Earnings ratio
26.94
Price-Earnings ratio26.94
Dividend yield
2.26%
Dividend yield2.26%
Average volume
2.36M
Average volume2.36M
High today
$440.51
High today$440.51
Low today
$429.38
Low today$429.38
Open price
$431.71
Open price$431.71
Volume
2.11M
Volume2.11M
52 Week high
$443.20
52 Week high$443.20
52 Week low
$269.77
52 Week low$269.77

Stock Snapshot

The current Amgen(AMGN) stock price is $439.06, with a market capitalization of 237.55B. The stock trades at a price-to-earnings (P/E) ratio of 26.94 and offers a dividend yield of 2.26%.

On 2026-08-21, Amgen(AMGN) stock traded between a low of $429.38 and a high of $440.51. Shares are currently priced at $439.06, which is +2.3% above the low and -0.3% below the high.

The Amgen(AMGN)'s current trading volume is 2.11M, compared to an average daily volume of 2.36M.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $443.20 at its peak.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $443.20 at its peak.

AMGN News

TipRanks 6h
Amgen Advances Tarlatamab Shot vs. Infusion in Phase 3 Lung Cancer Study

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Simply Wall St 14h
Is Amgen Fully Priced As Analysts Lift Targets After Second Quarter Results?

Advertisement Analyst moves put Amgen in focus Amgen (AMGN) is back on investors’ radar after Argus lifted its price target to $460 from $375 while keeping a...

Is Amgen Fully Priced As Analysts Lift Targets After Second Quarter Results?
TipRanks 1d
Amgen price target raised to $457 from $427 at Piper Sandler

Piper Sandler analyst David Amsellem raised the firm’s price target on Amgen (AMGN) to $457 from $427 and keeps an Overweight rating on the shares. The firm say...

Analyst ratings

50%

of 34 ratings
Buy
38.2%
Hold
50%
Sell
11.8%

More AMGN News

24/7 Wall St. 2d
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? By David Moadel Published Aug 19, 3:20PM EDT Quick Read Merck surged 44% YTD, topping Am...

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
TipRanks 2d
Amgen price target raised to $460 from $375 at Argus - TipRanks

...

Amgen price target raised to $460 from $375 at Argus - TipRanks
The Motley Fool 2d
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?

The Invesco Pharmaceuticals ETF (PJP +1.38%) offers concentrated exposure to U.S. drugmakers, while the Invesco Nasdaq Biotechnology ETF (IBBQ +0.93%) provides...

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?
TipRanks 3d
TScan Therapeutics Faces Loss of Key Amgen Partnership

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Simply Wall St 3d
The Bull Case For Amgen Could Change Following Raised 2026 Earnings Guidance And Q2 Beat - Learn Why

Amgen Inc. recently reported second-quarter 2026 results showing revenue of US$10,054 million and net income of US$2,375 million, and issued full-year 2026 guid...

The Bull Case For Amgen Could Change Following Raised 2026 Earnings Guidance And Q2 Beat - Learn Why
TipRanks 4d
Amgen’s Evolocumab Formulation Study Signals Steady Support for Its Cholesterol Franchise

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Simply Wall St 5d
Should Income Investors Look At Amgen Inc. Before Its Ex-Dividend?

Readers hoping to buy Amgen Inc. ( ) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date occ...

Should Income Investors Look At Amgen Inc. Before Its Ex-Dividend?

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.